Think Bioscience, Inc.

Programing microbial systems to discover, build, and evolve small-molecule drugs

Founded in 2021 by Jerome Fox, Matt Taylor and Philip Jeng, Think Bioscience is developing small-molecule therapeutics against challenging targets. The company harnesses microbial systems to evolve precisely targeted, readily synthesizable drug leads. Biosynthetic pathways from diverse sources are screened against a therapeutic target in a bacterial hybrid system where cell survival is linked to the inhibition of the target protein by the product of the biosynthetic pathway. Proof of concept was demonstrated against and “undruggable” target (PTP1B) implicated HER2+ breast cancer, diabetes, and obesity.